menu
    • menu
    [{"orgOrder":0,"company":"Catalysis","sponsor":"Atika Pharma S.L.","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Dietary Supplement","year":"2023","type":"Inapplicable","leadProduct":"Dipotassium Glycyrrhizinate","moa":"11-beta-hydroxysteroid dehydrogenase 1; Tumor necrosis factor; Caspase-3; Nuclear factor NF-kappa-B; Lipoprotein lipase","graph1":"Infections and Infectious Diseases","graph2":"Phase IV","graph3":"Catalysis","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Solution","sponsorNew":"Catalysis \/ Atika Pharma S.L.","highestDevelopmentStatusID":"11","companyTruncated":"Catalysis \/ Atika Pharma S.L."}]

    Find Clinical Drug Pipeline Developments & Deals for Dipotassium Glycyrrhizinate

    Menu

    Dipotassium Glycyrrhizinate

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    REF. STANDARDS & IMPURITIES

    ANALYTICAL

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Catalysis

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed

                            Catalysis

                            Country arrow
                            Aus. Peptide Conference
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Dipotassium Glycyrrhizinate

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase IV

                            Sponsor : Atika Pharma S.L.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation Of The Efficacy Of The Combination Of GLIZIGEN® Oral Solution 1/Day And Vaginal Gel 1/Night For ...

                            Details : Glizigen is a Dietary Supplement drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Papillomavirus Infections.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            June 23, 2023

                            Lead Product(s) : Dipotassium Glycyrrhizinate

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase IV

                            Sponsor : Atika Pharma S.L.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth